Data completeness
0/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALRELEASE is an oral extended-release capsule small-molecule drug developed by Roche with an unknown mechanism of action and indication portfolio. The product is a novel formulation in pre-launch stage, positioned to address unmet therapeutic needs through sustained-release technology. Patient population and therapeutic area cannot be determined from available data.
Pre-Launch
As a pre-launch asset from Roche, commercial teams are building infrastructure for market entry; headcount and budget allocation remain under development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VALRELEASE offers early-career opportunity to shape a new product launch from infrastructure build. Working on a pre-launch Roche asset provides exposure to full commercialization lifecycle, regulatory interactions, and cross-functional team dynamics.
Brand ManagerProduct Manager
Worked on VALRELEASE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.